Ivacaftor (benzenesulfonate) Size:Solid 2 mg Kinetics experiments revealed that PF-03716556

Kinetics experiments revealed that PF-03716556 has a competitive and reversible mode of action

Solubility: DMSO: ≥ 46 mg/mL

may down-regulate the phophorylation and activation of Erk1 and Erk2 in the Erk1/Erk2 Mapk signaling pathway

InChi: InChI=1S/C21H28O2/c1-4-21(23)12-9-18-16-6-5-14-13-15(22)7-10-19(14

is a new selective fluorescent indicator for hydrogen peroxide (H(2)O(2))

Ivacaftor (benzenesulfonate) Size:Solid 2 mg Kinetics experiments revealed that PF-03716556VX 770, is a drug used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, who account for 45% cases of cystic fibrosis, and is included in a combination drug, lumacaftor ivacaftor, which is used to treat people with cystic fibrosis who have the F508del mutation in CFTR. Ivacaftor is a "potentiator" of CFTR, meaning it increases the probability that the defective channel